Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Clinical trial NCT03707457 · TERMINATED
Trial details
- NCT number
- NCT03707457
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-22
- Primary completion
- 2019-11-30
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.